市場調查報告書

泌尿道感染 (UTI) 治療市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年

Urinary Tract Infection Treatment Market, By Drug Type, Quinolones, Cephalosporin, Azoles & Amphotericin B, & Other), Disease Indication, Distribution Channel, Region-Size, Share, Outlook, & Opportunity Analysis, 2020-2027

出版商 Coherent Market Insights 商品編碼 968700
出版日期 內容資訊 英文 197 Pages
商品交期: 2-3個工作天內
價格
泌尿道感染 (UTI) 治療市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年 Urinary Tract Infection Treatment Market, By Drug Type, Quinolones, Cephalosporin, Azoles & Amphotericin B, & Other), Disease Indication, Distribution Channel, Region-Size, Share, Outlook, & Opportunity Analysis, 2020-2027
出版日期: 2020年09月14日內容資訊: 英文 197 Pages
簡介

泌尿道感染(UTI)會導致細菌侵入尿道並感染膀胱,從而導致嚴重的健康問題。與男性相比,UTI感染是女性更常見的健康問題,主要是由於生物學因素造成的。

本報告提供全球泌尿道感染 (UTI) 治療市場相關調查分析,提供市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查目的與前提條件

第2章 市場範圍

第3章 市場動態·規定·趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的發展
  • 法規方案
  • PEST分析
  • COVID-19的影響分析

第4章 全球泌尿道感染 (UTI) 治療市場:各藥物類型

  • 簡介
  • 青霉素·複合藥
  • 奎諾酮類抗生素(Quinolones)
  • 頭孢菌素
  • Aminoglycosides系抗生素
  • 磺胺類藥物
  • Azole·Amphotericin B
  • 四環黴素
  • 硝基餡餅
  • 其他

第5章 全球泌尿道感染 (UTI) 治療市場:各適應症

  • 簡介
  • 複雜性UTI
  • 復發性複雜性UTI
  • 非複雜性UTI
  • 神經原因性膀胱感染疾病

第6章 全球泌尿道感染 (UTI) 治療市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球泌尿道感染 (UTI) 治療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
    • Cipla Ltd.
    • Johnson & Johnson
    • Bayer AG
    • Pfizer Inc.
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche Ltd.
    • Iterum Therapeutics plc
    • Novartis AG
    • AstraZeneca Plc
    • Allecra Therapeutics
    • Shionogi Inc.
    • Spero Therapeutics, Inc.
    • Venatorx Pharmaceuticals.

第9章 章節

目錄

Title:
Urinary Tract Infection Treatment Market, By Drug Type (Penicillin & Combinations (Amoxicillin, "Amoxicillin+ Clavulanate, Potassium", Others)), Quinolones (Ciprofloxacin, Levofloxacin, Nalidixic acid, Norfloxacin, Others), Cephalosporin (Ceftriaxone, Cefuroxime, Cefixime, Cephalexin), Aminoglycoside Antibiotics (Amikacin, Gentamicin), "Sulphonamides (Sulfamethoxazole +, Trimethoprim)", Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), Other), By Disease Indication (Complicated UTI, Recurring Complicated UTI, Uncomplicated UTI, Neurogenic Bladder Infections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.

Restraints of the Global Urinary Tract Infection Treatment Market

Major factors hampering the growth of the urinary tract infection treatment market during the forecast period constitutes of low adoption of internet in some emerging economies.

Key features of the study:

  • This report provides in-depth analysis of the global urinary tract infection treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global urinary tract infection treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global urinary tract infection treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Urinary Tract Infection Treatment Market, By Drug Type:
    • Penicillin & Combinations
  • Amoxicillin
  • "Amoxicillin+ Clavulanate
  • Potassium"
  • Others
    • Quinolones
  • Ciprofloxacin
  • Levofloxacin
  • Nalidixic acid
  • Norfloxacin
  • Others
    • Cephalosporin
  • Ceftriaxone
  • Cefuroxime
  • Cefixime
  • Cephalexin
    • Aminoglycoside Antibiotics
  • Amikacin
  • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • Global Urinary Tract Infection Treatment Market, By Disease Indication:
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • Global Urinary Tract Infection Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Urinary Tract Infection Treatment Market, By Geography:
    • North America
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • Cipla Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • Johnson & Johnson
    • Bayer AG
    • Pfizer Inc.
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche Ltd.
    • Iterum Therapeutics plc
    • Novartis AG
    • AstraZeneca Plc
    • Allecra Therapeutics
    • Shionogi Inc.
    • Spero Therapeutics, Inc.
    • Venatorx Pharmaceuticals.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global Urinary Tract Infection Treatment Market, By Drug Type, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Penicillin & Combinations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Amoxicillin
    • Amoxicillin+ Clavulanate
    • Potassium"
    • Others
    • Quinolones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Ciprofloxacin
    • Levofloxacin
    • Nalidixic acid
    • Norfloxacin
    • Others
    • Cephalosporin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Ceftriaxone
    • Cefuroxime
    • Cefixime
    • Cephalexin
    • Aminoglycoside Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Amikacin
    • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other

5. Global Urinary Tract Infection Treatment Market, By Disease Indication, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Complicated UTI
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Recurring Complicated UTI
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Uncomplicated UTI
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Neurogenic Bladder Infections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Urinary Tract Infection Treatment Market, By Distribution Channel, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Urinary Tract Infection Treatment Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

    • Company Profiles
  • Cipla Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Iterum Therapeutics plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Allecra Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shionogi Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Spero Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Venatorx Pharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact